The European Journal of Pharmaceutical and Medical Research (EJPMR) has published a study on the clinical effects of Absocurcumin, a flagship Botanic Healthcare product.
This randomized, double-blind, placebo-controlled clinical study assessed the pain-relief effects of Absocurcumin on patients with osteoarthritis (OA) of the knee. It found that treatment significantly reduced the pain compared with placebo control and there was improvement in stiffness and physical function when compared to baseline.
The findings from the study provide clinical evidence to support that biologically active component of Absocurcumin exerted analgesic and anti-inflammatory activity, reducing joint pain and improving physical functional ability. No serious adverse events were observed, thus supporting the pharmacological safety of Absocurcumin to be considered as a viable candidate for the treatment of OA of the knee.
Absocurcumin is a high-quality organic extract of turmeric (Curcuma longa). Botanic Healthcare developed this product using our unique extraction process that optimizes the yield and efficacy of active ingredients.
OA is the most common degenerative joint disease in the world, affecting more than 25% of the US population over 18 years old. It causes moderate-to-severe disability in 43 million people, making it the 11th most debilitating disease around the world. AbsoCurcumin may offer a safe option for relief from symptoms and increased mobility for those with OA.
Read the EJPMR article online: